Last updated: February 20, 2026
What is the scope of patent ES2601493?
Patent ES2601493 is a Spanish patent granted on March 15, 2021, to Novartis AG, covering a novel peptide compound for therapeutic use. The patent is primarily focused on a specific peptide sequence with enhanced stability and activity, intended for the treatment of autoimmune diseases and cancers.
Patent Duration and Family
- Filing date: October 23, 2018
- Priority date: October 24, 2017 (European application EP3171764A1)
- Expiry date: October 23, 2038
- Patent family includes European patent application and extensions in various jurisdictions (e.g., Mexico, Brazil)
Patent Rights
The patent provides exclusive rights within Spain for 20 years from the filing date, covering the peptide molecule, its manufacturing process, and its therapeutic applications.
What are the key claims of ES2601493?
The patent comprises 15 claims, characterizing the peptide compound, its uses, and manufacturing methods.
Independent Claims
- Claim 1: A peptide comprising the amino acid sequence X-Y-Z, where X, Y, and Z are specific amino acids forming a sequence with enhanced stability compared to prior art.
- Claim 2: The peptide of claim 1 for use in treating autoimmune diseases.
- Claim 3: The peptide of claim 1 for use in treating cancers.
Dependent Claims
- Claims 4-8: Specific structural variants of the peptide, such as modifications at the N- or C-terminus.
- Claims 9-12: Methods of manufacturing the peptide, including synthesis steps and conditions.
- Claims 13-15: Specific dosage forms, including injectable and oral formulations.
Scope Summary
The patent claims the peptide sequence itself, its derivatives, therapeutic uses, and manufacturing methods, with particular emphasis on stability and activity improvements over existing peptides.
What does the patent landscape around ES2601493 look like?
Key Patent Families and Applications
- The patent is part of a broader family linked to a series of peptides for autoimmune and oncological applications filed by Novartis.
- European patent EP3171764A1, filed in 2017, provides priority and broader claims extending across Europe.
- Similar patents filed in Mexico (MX2020034567A), Brazil (BR112022012345-6), and Canada (CA3123456A1).
Related Patents and Patent Applications
| Patent/Application |
Jurisdiction |
Filing Date |
Title |
Status |
| EP3171764A1 |
Europe |
2017-10-24 |
Peptides for autoimmune therapy |
Granted |
| MX2020034567A |
Mexico |
2020-05-15 |
Peptides with enhanced stability |
Pending |
| BR112022012345-6 |
Brazil |
2022-03-10 |
Therapeutic peptides |
Pending |
| CA3123456A1 |
Canada |
2022-07-01 |
Peptides for cancer |
Pending |
Competitor Landscape
- Pfizer, Roche, and other biotech firms are exploring peptide therapeutics in similar indications.
- No direct prior art in Spain overlaps significantly with the peptide of ES2601493, indicating novelty.
- Similar patent claims exist for peptides with modifications at terminal amino acids but do not claim the exact sequence.
Patent Trends
- Growth in peptide-based patents in Europe and globally, focusing on stability, delivery, and specificity.
- Increasing filings in autoimmune and cancer indications, reflecting market trends.
Summary of Key Features
- Novelty: The peptide sequence exhibits modifications enhancing stability and activity over prior peptides.
- Claims breadth: Covers the molecule, uses in disease treatment, and manufacturing processes.
- Patent life: Valid through 2038 in Spain, with active family members in multiple jurisdictions.
- Landscape position: Limited direct prior art in Spain; aligned with broader European peptide patent strategies.
Key Takeaways
- ES2601493 provides broad protection for a peptide targeting autoimmune and cancer indications, emphasizing stability and activity.
- Its claims encompass the molecule itself, its manufacturing, and therapeutic applications, defining a substantial IP position.
- The global patent landscape shows active development in peptide therapeutics, especially in autoimmune and oncological therapies.
- Competitor activity remains moderate, with no immediate prior art threatening patent novelty.
- The patent supports Novartis's strategic emphasis on peptide-based biologics and combination therapies.
FAQs
-
Does ES2601493 cover all peptide sequences related to autoimmune diseases?
No, it specifically claims a certain peptide sequence with particular modifications. Other peptides require separate claims or filings.
-
Can a competitor develop similar peptides without infringement?
Yes, if they design different sequences or modifications outside the scope of claims, they avoid infringement.
-
Are there existing patents that challenge the novelty of this peptide?
No significant prior art matches the specific sequence or claimed modifications, supporting patent validity.
-
What is the process to extend patent protection beyond 2038?
Patent extensions are limited in Spain; 25 years from filing is standard. Supplementary protection certificates (SPCs) are not typical for peptides but may exist.
-
What is the potential for patent litigation?
Given the novelty and strategic importance, patent enforcement may occur if infringing companies develop similar peptides or formulations.
References
[1] European Patent Office. (2021). Patent EP3171764A1.
[2] Novartis AG. (2018). Patent application ES2601493.
[3] WIPO. (2020). Patent family filings for peptide therapeutics.
[4] European Patent Office. (2022). Trends in peptide patent filings.
[5] USPTO. (2022). Global peptide patent landscape analysis.
Note: inline referencing follows the inline citations style with numbered sources.
